<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880031</url>
  </required_header>
  <id_info>
    <org_study_id>BOS-580-201</org_study_id>
    <nct_id>NCT04880031</nct_id>
  </id_info>
  <brief_title>A Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A 12-week Phase 2a Randomized, Blinded, Placebo Controlled Study of BOS-580 in Obese Subjects at Risk for Nonalcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety study to evaluate BOS-580 administered subcutaneously over 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAE) and treatment-emergent serious adverse events (TESAE)</measure>
    <time_frame>Until End of study/Early Termination (Day 113)</time_frame>
    <description>The effects of BOS-580 on safety and tolerability will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline to Week 12 (Day 85) in systolic and diastolic blood pressure (BP)</measure>
    <time_frame>Baseline, Week 12 (Day 85)</time_frame>
    <description>The effects of BOS-580 on safety and tolerability will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from Baseline to Week 12 (Day 85) in heart rate</measure>
    <time_frame>Baseline, Week 12 (Day 85)</time_frame>
    <description>The effects of BOS-580 on safety and tolerability will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Grade 3-4 laboratory abnormalities at Week 12 (Day 85)</measure>
    <time_frame>Week 12 (Day 85)</time_frame>
    <description>The effects of BOS-580 on safety and tolerability will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum drug concentration (Cmax) for BOS-580</measure>
    <time_frame>At Days 1, 15, 29, 43, 57, 85 (Pre-dose), at Day 8, and at End of study/Early Termination (Day 113)</time_frame>
    <description>The pharmacokinetics (PK) of BOS-580 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum serum drug concentration (Cmin) for BOS-580</measure>
    <time_frame>At Days 1, 15, 29, 43, 57, 85 (Pre-dose), at Day 8, and at End of study/Early Termination (Day 113)</time_frame>
    <description>The PK of BOS-580 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average serum drug concentration (Cavg) for BOS-580</measure>
    <time_frame>At Days 1, 15, 29, 43, 57, 85 (Pre-dose), at Day 8, and at End of study/Early Termination (Day 113)</time_frame>
    <description>The PK of BOS-580 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum serum concentration (Tmax) for BOS-580</measure>
    <time_frame>At Days 1, 15, 29, 43, 57, 85 (Pre-dose), at Day 8, and at End of study/Early Termination (Day 113)</time_frame>
    <description>The PK of BOS-580 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve (AUC) from time zero to time of last measurable concentration (AUClast) for BOS-580</measure>
    <time_frame>At Days 1, 15, 29, 43, 57, 85 (Pre-dose), at Day 8, and at End of study/Early Termination (Day 113)</time_frame>
    <description>The PK of BOS-580 will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve during a dosage interval (AUCtau) for BOS-580</measure>
    <time_frame>At Days 1, 15, 29, 43, 57, 85 (Pre-dose), at Day 8, and at End of study/Early Termination (Day 113)</time_frame>
    <description>The PK of BOS-580 will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Nonalcoholic Steatohepatitis (NASH)</condition>
  <arm_group>
    <arm_group_label>Cohort A1: BOS-580 Dose 1 or placebo (PBO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: BOS-580 Dose 2 or PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: BOS-580 Dose 3 or PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4: BOS-580 Dose 4 or PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5: BOS-580 Dose 5 or PBO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOS-580</intervention_name>
    <description>BOS-580 will be administered by subcutaneous injection</description>
    <arm_group_label>Cohort A1: BOS-580 Dose 1 or placebo (PBO)</arm_group_label>
    <arm_group_label>Cohort A2: BOS-580 Dose 2 or PBO</arm_group_label>
    <arm_group_label>Cohort A3: BOS-580 Dose 3 or PBO</arm_group_label>
    <arm_group_label>Cohort A4: BOS-580 Dose 4 or PBO</arm_group_label>
    <arm_group_label>Cohort A5: BOS-580 Dose 5 or PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered by subcutaneous injection</description>
    <arm_group_label>Cohort A1: BOS-580 Dose 1 or placebo (PBO)</arm_group_label>
    <arm_group_label>Cohort A2: BOS-580 Dose 2 or PBO</arm_group_label>
    <arm_group_label>Cohort A3: BOS-580 Dose 3 or PBO</arm_group_label>
    <arm_group_label>Cohort A4: BOS-580 Dose 4 or PBO</arm_group_label>
    <arm_group_label>Cohort A5: BOS-580 Dose 5 or PBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is either male or female and 18 to 75 years of age inclusive, at the time&#xD;
             of signing the informed consent&#xD;
&#xD;
          -  Obese participants with body mass index (BMI) within the range of 30 to 45 kg/m^2&#xD;
             (inclusive)&#xD;
&#xD;
          -  Hepatic fat fraction (HFF) measured by magnetic resonance imaging derived proton&#xD;
             density fat fraction (MRI-PDFF) &gt; 10%&#xD;
&#xD;
          -  Liver injury and fibrosis assessment based on vibration controlled transient&#xD;
             elastography (VCTE) liver stiffness measurement (LSM) score and aspartate&#xD;
             aminotransferase (AST).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented clinical, laboratory or radiologic evidence of cirrhosis (compensated or&#xD;
             decompensated)&#xD;
&#xD;
          -  Triglycerides â‰¥ 500 mg/dL&#xD;
&#xD;
          -  Change in body weight (more than 5% self-reported OR 5 kg self-reported change during&#xD;
             the previous 3 months from Screening)&#xD;
&#xD;
          -  History of type 1 diabetes, diabetic ketoacidosis, or positive glutamic acid&#xD;
             decarboxylase (GAD) auto-antibodies (latent autoimmune diabetes in adults)&#xD;
&#xD;
          -  Hemoglobin A1c &gt; 9.5%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Etienne Dumont, MD</last_name>
    <phone>(484) 986 8699</phone>
    <email>clinicaltrials@bostonpharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Research Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>QLMC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest General Healthcare Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galenus Group</name>
      <address>
        <city>Lehigh Acres</city>
        <state>Florida</state>
        <zip>33976</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panex Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lovelace</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lillestol Research LLC</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accelemed Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centex Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Olympus Family Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Ogden Family Medicine</name>
      <address>
        <city>South Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BOS-580</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

